Details for Patent: 5,886,035
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 5,886,035 protect, and when does it expire?
Patent 5,886,035 protects ZIOPTAN and is included in one NDA.
This patent has twenty patent family members in thirteen countries.
Summary for Patent: 5,886,035
Title: | Difluoroprostaglandin derivatives and their use |
Abstract: | A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: ##STR1## wherein A is a vinylene group or the like, R.sup.1 is an aryloxyalkyl group or the like, R.sup.2 and R.sup.3 are hydrogen atoms or the like, and Z is OR.sup.4 (wherein OR.sup.4 is a hydrogen atom or an alkyl group) or the like. |
Inventor(s): | Shirasawa; Eiichi (Ikoma, JP), Kageyama; Masaaki (Ikoma, JP), Nakajima; Tadashi (Ikoma, JP), Nakano; Takashi (Yokohama, JP), Mori; Nobuaki (Yokohama, JP), Sasakura; Hideshi (Yokohama, JP), Matsumura; Yasushi (Yokohama, JP), Morizawa; Yoshitomi (Yokohama, JP) |
Assignee: | Asahi Glass Company Ltd. (Tokyo, JP) Santen Pharmaceutical Co., Ltd. (Osaka, JP) |
Application Number: | 08/993,017 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 5,886,035 |
Patent Claim Types: see list of patent claims | Compound; Use; |
Drugs Protected by US Patent 5,886,035
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Thea Pharma | ZIOPTAN | tafluprost | SOLUTION/DROPS;OPHTHALMIC | 202514-001 | Feb 10, 2012 | AT | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | See Plans and Pricing | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 5,886,035
International Family Members for US Patent 5,886,035
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 225770 | See Plans and Pricing | |||
Canada | 2225761 | See Plans and Pricing | |||
China | 1108289 | See Plans and Pricing | |||
China | 1187486 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |